Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1997 1
1998 1
2009 2
2010 1
2011 3
2012 2
2015 1
2022 1
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Pirfenidone in idiopathic pulmonary fibrosis.
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, Taguchi Y, Takahashi H, Nakata K, Sato A, Takeuchi M, Raghu G, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Eur Respir J. 2010 Apr;35(4):821-9. doi: 10.1183/09031936.00005209. Epub 2009 Dec 8. Eur Respir J. 2010. PMID: 19996196 Free article. Clinical Trial.
A Telemedicine Approach for Monitoring COPD: A Prospective Feasibility and Acceptability Cohort Study.
Shinoda M, Hataji O, Miura M, Kinoshita M, Mizoo A, Tobino K, Soutome T, Nishi T, Ishii T, Miller BE, Tal-Singer R, Tomlinson R, Matsuki T, Jones PW, Shibata Y. Shinoda M, et al. Among authors: mizoo a. Int J Chron Obstruct Pulmon Dis. 2022 Nov 17;17:2931-2944. doi: 10.2147/COPD.S375049. eCollection 2022. Int J Chron Obstruct Pulmon Dis. 2022. PMID: 36419950 Free PMC article.
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.
Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Azuma A, et al. Respir Res. 2011 Oct 28;12(1):143. doi: 10.1186/1465-9921-12-143. Respir Res. 2011. PMID: 22035508 Free PMC article. Clinical Trial.
Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study.
Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K, Tokuda H, Yamaguchi T, Mizoo A, Setoguchi Y, Kamigaki T, Fujimoto K, Goto S. Iwai K, et al. Among authors: mizoo a. Cancer Immunol Immunother. 2012 Oct;61(10):1781-90. doi: 10.1007/s00262-012-1226-4. Epub 2012 Mar 16. Cancer Immunol Immunother. 2012. PMID: 22422103 Free PMC article. Clinical Trial.
Health Status Progression Measured Using Weekly Telemonitoring of COPD Assessment Test Scores Over 1 Year and Its Association With COPD Exacerbations.
Jones P, Soutome T, Matsuki T, Shinoda M, Hataji O, Miura M, Kinoshita M, Mizoo A, Tobino K, Nishi T, Ishii T, Shibata Y. Jones P, et al. Among authors: mizoo a. Chronic Obstr Pulm Dis. 2024 Mar 26;11(2):144-154. doi: 10.15326/jcopdf.2023.0415. Chronic Obstr Pulm Dis. 2024. PMID: 38442134 Free PMC article.
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Respir Res. 2011 Jul 15;12(1):93. doi: 10.1186/1465-9921-12-93. Respir Res. 2011. PMID: 21756364 Free PMC article. Clinical Trial.
14 results